Could two novel biomarkers change the standard in care and treatment of pancreatic ductal adenocarcinomas? Recent research suggests a change in preoperative prognoses and a step forward in personalized medicine.
Charles River Laboratories (MA, USA) have acquired Brains On-Line (CA,USA), a CRO specializing in therapeutics for the treatment of CNS diseases.
Novel technology, using single-color digital PCR, could enable the detection of cancerous DNA in circulating blood.
Panicos Kyriacou, a professor at City, University of London, UK, is leading the design and development of a novel optical sensor for the continuous monitoring of lactate in blood.
The journal, the Society for Laboratory Automation and Screening Technology, presents a special issue highlighting the development of research assays.
Researchers have identified a new biomarker for a group of rare metabolic disorders, mucopolysaccharidoses, which could facilitate better diagnosis.
Researchers have identified new biomarkers that could aid stage-specific diagnosis of Alzheimer’s, leading to advancements in treatment.
Boehringer Ingelheim has announced that the interchangeability study for their adalimumab biosimilar candidate has begun.
Thermo Fisher Scientific (MA, USA) have developed a new series of quality assured leak-proof vials that offer enhanced sample protection and user safety.
Researchers have tested the efficacy of serum samples in comparison with dried blood spots when used in longitudinal studies.